Gallagher Fiduciary Advisors LLC Buys Shares of 5,508 AbbVie Inc. $ABBV

Key Points

• Gallagher Fiduciary Advisors initiated a position in AbbVie, purchasing 5,508 shares valued at approximately $1.39 million. Other institutional investors also added shares, with hedge funds and institutions collectively owning 70.23% of the stock.
• Analysts remain generally bullish, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $275.95. Several firms recently raised their targets to between $285 and $300.
• AbbVie exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue, while declaring a quarterly dividend of $1.73 per share, or $6.92 annualized.

Gallagher Fiduciary Advisors LLC bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,508 shares of the company's stock, valued at approximately $1,386,000.

Several other hedge funds have also modified their holdings of ABBV. Sonoma Private Wealth LLC bought a new stake in shares of AbbVie in the 2nd quarter valued at about $854,000. Invst LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $659,000. Councilmark Asset Management LLC purchased a new stake in AbbVie during the second quarter valued at approximately $2,803,000. First Bancorp Inc ME acquired a new stake in AbbVie in the second quarter valued at approximately $825,000. Finally, Roberts Glore & Co. Inc. IL acquired a new stake in AbbVie in the second quarter valued at approximately $7,412,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Morgan Stanley reiterated an "overweight" rating and issued a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. BMO Capital Markets upped their price target on shares of AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. BNP Paribas Exane lifted their price target on AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald raised their target price on AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie Trading Down 1.5%

NYSE:ABBV opened at $256.27 on Friday. The stock has a 50 day moving average of $254.66 and a two-hundred day moving average of $230.06. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The firm has a market cap of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is 195.48%.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source